Document Detail

Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin.
MedLine Citation:
PMID:  15623184     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Interferon alpha (IFN-alpha) with or without ribavirin is an approved therapy for patients with chronic hepatitis C. However, a sustained response is achieved in less than 40% of all treated cases. Retreatment of relapsers or non-responders usually fails. Thymosin alpha 1 (Ta-1) is a polypeptide with immunomodulatory properties that has been suggested to increase response rates in patients with chronic hepatitis C. The aim of present study was to evaluate the efficacy of a novel triple regimen which includes Ta-1 for relapsers and non-responders to the combination of TA-1 and ribavirin. METHODS: In the present study, 11 patients who relapsed (n=5) or did not respond (n=6) to previous INF-alpha-based therapy were retreated with combination Ta-1, INF-alpha and ribavirin for 12 months, and followed up for a further six months. RESULTS: Four out of five relapsers had a sustained response. One of the non-responders cleared the HCV RNA during the post-treatment follow-up. Minor adverse effects were observed during treatment with this combination therapy and no dose reduction or discontinuations were needed. CONCLUSION: This data suggests that thymosin alpha 1 may add to the efficacy of INF-alpha plus ribavirin in the retreatment of relapsers or non-responders to previous INF-alpha-based hepatitis C therapy.
Z Abbas; S S Hamid; S Tabassum; W Jafri
Related Documents :
20170514 - Short versus standard treatment with pegylated interferon alfa-2a plus ribavirin in pat...
18030234 - Liver histology of children with chronic hepatitis treated with interferon-alpha alone ...
18397484 - Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had ...
20087154 - Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive a...
7586604 - Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women?
10382124 - Pretreatment antibiotic resistance in helicobacter pylori infection: results of three r...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  JPMA. The Journal of the Pakistan Medical Association     Volume:  54     ISSN:  0030-9982     ISO Abbreviation:  J Pak Med Assoc     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2004-12-29     Completed Date:  2005-02-01     Revised Date:  2008-02-12    
Medline Journal Info:
Nlm Unique ID:  7501162     Medline TA:  J Pak Med Assoc     Country:  Pakistan    
Other Details:
Languages:  eng     Pagination:  571-4     Citation Subset:  IM    
Department of Medicine, The Aga Khan University Hospital, Karachi.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adjuvants, Immunologic / therapeutic use*
Antiviral Agents / therapeutic use*
Drug Therapy, Combination
Hepatitis C, Chronic / drug therapy*,  immunology
Interferon-alpha / therapeutic use*
Middle Aged
Ribavirin / therapeutic use*
Thymosin / analogs & derivatives*,  therapeutic use*
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Antiviral Agents; 0/Interferon-alpha; 0/thymalfasin; 36791-04-5/Ribavirin; 61512-21-8/Thymosin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Anaesthesia for surgical correction of scoliosis with spinal cord monitoring--a case series.
Next Document:  Non-endoscopic parameters for the identification of esophageal varices in patients with chronic hepa...